Navigation Links
Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of California's Individual, Small Group, and Government Business Unit
Date:9/10/2007

ndependent member of the Blue Shield Association, is a not-for-profit health plan dedicated to providing Californians with access to high quality care at a reasonable price. Founded in 1939, it now has 3.2 million members, 4,500 employees, one of the largest provider networks and more than 20 office locations, providing a wide range of commercial and government products throughout the state. The company contributes $30 million annually to the Blue Shield of California Foundation to fund nonprofit organizations that improve access to quality health care in California. Contact your local agent or broker for more information about Blue Shield products and services, or visit the Blue Shield web site at http://www.blueshieldca.com.

CONTACT: Ashley Wilkerson

Public Affairs Associate

(310) 744-2661

ashley.wilkerson@blueshieldca.com


'/>"/>
SOURCE Blue Shield of California
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. A Killer Clot, Coagulates Karen’s Lif
2. FDA needs to be more vigilant in monitoring, tissue banks.
3. Strict Vigilance against Bird Flu in Hong Kong
4. Provigil Patent Extension Accorded To Cephalon
5. Study Focus on the Need for Vigilance in Two Key Areas Among Adolescents
6. India Fast Become Prime Location for Clinical Trials, but Vigilance Called for
7. France Steps Up Vigilance After Bird Flu Outbreak
8. UP government decides to suspend doctor named in sting operation
9. Yale Researchers Named Ellison Foundation Senior Scholars in Aging
10. Brian Lara Opens Cancer Center Named After Him
11. Bat Virus Renamed After Protests from Malaysia State
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 1Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 2Uroplasty Reports First Fiscal Quarter Results 53547 1Uroplasty Reports First Fiscal Quarter Results 53547 2Uroplasty Reports First Fiscal Quarter Results 53547 3Uroplasty Reports First Fiscal Quarter Results 53547 4Uroplasty Reports First Fiscal Quarter Results 53547 5Uroplasty Reports First Fiscal Quarter Results 53547 6Uroplasty Reports First Fiscal Quarter Results 53547 7Uroplasty Reports First Fiscal Quarter Results 53547 8Uroplasty Reports First Fiscal Quarter Results 53547 9Uroplasty Reports First Fiscal Quarter Results 53547 10Uroplasty Reports First Fiscal Quarter Results 53547 11Uroplasty Reports First Fiscal Quarter Results 53547 12Uroplasty Reports First Fiscal Quarter Results 53547 13Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 1Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 2Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 3Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 4Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 5Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 6Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 7Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 8Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 9Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 10